Marmont A M, Cerri R, Lercari G, Van Lint M T, Bacigalupo A, Risso M
Acta Haematol. 1985;74(1):14-8. doi: 10.1159/000206156.
Forty-six patients with severe aplastic anemia (SAA), 1 with adult pure red cell aplasia (PRCA), 1 with congenital hypoplastic anemia (Diamond-Blackfan) and 1 with severe polymyositis were treated with intravenous antilymphocyte globulins (ALG) of different sources (2 of equine and 1 of rabbit origin). In all patients, direct and indirect antiglobulin tests (DAT and IAT) were performed, and in all patients treated with one type of equine ALG, positive DATs were found in Rh0(D)-positive patients, while the serum of Rh0(D)-negative patients treated with the same ALG reacted in vitro with Rh0(D)-positive erythrocytes. The antibody was eluted and shown to be of equine origin. Two patients suffered from frank heteroimmune hemolytic anemia. Since October 1984, the ALG of this particular source has not displayed any overt anti-erythrocyte activity any more. However, all clinicians treating patients with this type of immune immunosuppression should know that ALG may retain human erythrocyte (presumably anti-LW) activity.
46例重型再生障碍性贫血（SAA）患者、1例成人纯红细胞再生障碍性贫血（PRCA）患者、1例先天性再生障碍性贫血（戴蒙德-布莱克范贫血）患者和1例重症多发性肌炎患者接受了不同来源的静脉注射抗淋巴细胞球蛋白（ALG）治疗（马源2例，兔源1例）。对所有患者均进行了直接和间接抗球蛋白试验（DAT和IAT），在用一种马源ALG治疗的所有患者中，Rh0（D）阳性患者的DAT呈阳性，而用相同ALG治疗的Rh0（D）阴性患者的血清在体外与Rh0（D）阳性红细胞发生反应。洗脱的抗体显示为马源。2例患者出现明显的异基因免疫性溶血性贫血。自1984年10月以来，这种特定来源的ALG不再表现出任何明显的抗红细胞活性。然而，所有使用这种免疫抑制疗法治疗患者的临床医生都应该知道，ALG可能会保留人红细胞（可能是抗LW）活性。
